Table 2.
Distribution of first-line chemotherapy regimens among stage IB+ MCL patients up to 65 y of age at diagnosis in Sweden between January 2000 and June 2014, by selection to treatment with AHCT within 18 mo of diagnosis
| Treatment | n (col %) | AHCT ≤18 mo (col %) | No AHCT ≤18 mo (col %) |
|---|---|---|---|
| NLG-MCL2/MCL3 protocol | 193 (52.3) | 165 (74.7) | 28 (18.9) |
| R-CHOP alternating with R-cytarabine or R-cytarabine single* | 16 (4.3) | 4 (1.8) | 12 (8.1) |
| R-CHOP/CHOEP/COP* | 38 (10.3) | 5 (2.3) | 33 (22.3) |
| Chlorambucil | 12 (3.3) | 0 (0.0) | 12 (8.1) |
| R-fludarabine/cyclophosphamide* | 4 (1.1) | 0 (0.0) | 4 (1.1) |
| R-bendamustine* | 4 (1.1) | 0 (0.0) | 4 (1.1) |
| Wait and watch | 10 (2.7) | 0 (0.0) | 10 (6.8) |
| Radiotherapy only | 7 (1.9) | 0 (0.0) | 7 (4.7) |
| Other treatment† | 4 (1.1) | — | — |
| Missing | 81 (22.0) | 46 (20.8) | 35 (23.7) |
| Total | 369 (100) | 221 (100) | 148 (100) |
Due to rounding, not all percentages add up to 100.
CHO(E)P, cyclophosphamide, vincristine, doxorubicin (etoposide), and prednisone; NLG-MCL2/MCL3 protocol Nordic lymphoma group: mantle cell lymphoma 2 and 3 protocol containing dose-intensified cyclophosphamide, vincristine, doxorubicin, and prednisone in combination with rituximab alternating high-dose cytarabine.
12 out of 16 patients received rituximab in the CHOP/cytarabine group; 23 out of 38 in the CHOP/CHOEP/COP group; 1 out of 4 in the fludarabine/cyclophosphamide group, and all patients in the bendamustine group.
Either R-bendamustine alternating with R-cytarabine, or unspecified chemotherapy; detailed frequencies not shown in subgroups due to cell count <4.